MAP3K7 and systemic sclerosis: Recalling the earlier cited comments of Longaker and colleagues [78] on the need for small molecule therapeutics development in this area, we suggest that small molecule inhibitors of TAK1 being investigated for limiting fibrosis in SSc may result in fruitful studies on the regulation of excess matrix deposition in scarring and keloid formation.